GSA Capital Partners LLP Trims Stock Position in Neumora Therapeutics, Inc. $NMRA

GSA Capital Partners LLP trimmed its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 88.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 108,411 shares of the company’s stock after selling 795,332 shares during the quarter. GSA Capital Partners LLP’s holdings in Neumora Therapeutics were worth $197,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Legacy Private Trust Co. purchased a new stake in Neumora Therapeutics in the third quarter worth about $25,000. CWM LLC raised its position in shares of Neumora Therapeutics by 41.8% in the 2nd quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after acquiring an additional 10,537 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in shares of Neumora Therapeutics in the 2nd quarter valued at approximately $29,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Neumora Therapeutics during the second quarter valued at approximately $41,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Neumora Therapeutics during the second quarter valued at approximately $41,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Insiders Place Their Bets

In related news, insider Paul L. Berns sold 9,819 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. This represents a 0.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 23,387 shares of company stock valued at $82,647. 26.80% of the stock is owned by insiders.

Neumora Therapeutics Stock Down 1.7%

Shares of Neumora Therapeutics stock opened at $3.49 on Monday. The company has a 50-day simple moving average of $2.37 and a two-hundred day simple moving average of $2.15. The stock has a market capitalization of $583.14 million, a PE ratio of -2.37 and a beta of 2.46. Neumora Therapeutics, Inc. has a 52-week low of $0.61 and a 52-week high of $3.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85.

Analyst Ratings Changes

NMRA has been the subject of a number of research reports. Leerink Partners initiated coverage on Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price objective for the company. Stifel Nicolaus lifted their price target on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Finally, William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.13.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.